Eptifibatide Acetate
Synonym(s):Cyclo(S,S)-Mpr(Har)GDWPC-NH2 acetate;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (16)-disulfide acetate
- CAS NO.:148031-34-9
- Empirical Formula: C35H49N11O9S2
- Molecular Weight: 831.96
- MDL number: MFCD05662245
- EINECS: 1533716-785-6
- SAFETY DATA SHEET (SDS)
- Update Date: 2025-04-29 17:45:46
What is Eptifibatide Acetate?
The Uses of Eptifibatide Acetate
The acetate salt form of eptifibatide (E592000), an arginine-glycine-aspartate-mimetic which reversibly binds to platelets to reduce the risk of cardiac ischemic events.
What are the applications of Application
Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-Llysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1→6)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation.
The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is:
Indications
Acute Coronary Syndrome (ACS)
INTEGRILIN? is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI).
Percutaneous Coronary Intervention (PCI)
INTEGRILIN is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.
Dosage forms
Before infusion of INTEGRILIN, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured.
The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT.
Properties of Eptifibatide Acetate
| Melting point: | >220°C (dec.) |
| storage temp. | Refrigerator |
| solubility | DMSO (Slightly), Methanol (Slightly), Water (Slightly) |
| form | Solid |
| color | White to Off-White |
| CAS DataBase Reference | 148031-34-9(CAS DataBase Reference) |
Safety information for Eptifibatide Acetate
Computed Descriptors for Eptifibatide Acetate
New Products
Cyclopentane-1,2-dione 2,6-Dibromoaniline 5-Hydroxy-3,9-dimethyl-7H-benzo[c]fluoren-7-one Methyl 4-(acetyloxy)-6-methoxy-1-(4-methoxyphenyl)-2naphthalenecarboxylate 4-Hydroxy-6,7-dimethoxy-1-phenyl-2naphthalenecarboxylic acid (3,5-Dibromophenyl)[4-(trifluoromethyl)phenyl]methanone (4-butoxyphenyl)(4-fluorophenyl)methanone (4-Bromophenyl)(3,4-dimethoxyphenyl)methanone Cefuroxime EP Impurity-A N-Nitroso hydroxy Cetrizine EP Impurity-A Noradrenaline EP Impurity D/Noradrenaline Methyl Ether Cetirizine EP Impurity A/Cetirizine CBHP Impurity Lantanoprost rc B Clidinium Bromide Impurity Benzyl-N,4-dimethylpiperidine-3- amine dihydrochloride 3-(4-phenoxyphenyl)-1H- pyrazolo[3,4- d]pyrimidin-4- amine 4-Ethyl-4-hydroxy-1,4,7,8-tetrahydro-3H,10H-spiro[pyrano[3,4-f]indolizine-6,2'-[1,3]dioxolane]-3,10-dione (E)-N'-(2-cyano-4-nitrophenyl)- N,N-dimethylformimidamide N-(8-Amino-6-fluoro-5-methyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide 5-bromopyridin-2-amine 2-Chloro Benzylcyanide 3-chlorobenzyl cyanide 3,4 Diethoxy Benzylcyanide 3,4 Dimethoxy BenzylcyanideRelated products of tetrahydrofuran








You may like
-
Eptifibatide 98%View Details -
151239-47-3 98+View Details
151239-47-3 -
4-Hydroxy-6-methyl-1-(4-methylphenyl)-2naphthalenecarboxylic acid 98+View Details
101894-09-1 -
83883-25-4 98+View Details
83883-25-4 -
(3,5-dibromophenyl)(4-methoxyphenyl)methanone 1991533-97-1 98+View Details
1991533-97-1 -
54598-15-1 4,5,7-Trimethyl-2(1H)-quinolinone 98+View Details
54598-15-1 -
4-(6-HYDROXYHEXYLOXY)BENZOIC ACID 83883-25-4 98+View Details
83883-25-4 -
2-[4-(1,1-Dimethylethyl)-2-naphthalenyl]-4,4,5,5tetramethyl-1,3,2-dioxaborolane 98+View Details
2217657-10-6
